By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.
A p75 neurotrophin receptor fusion protein reduces pain and improves function in patients with knee osteoarthritis across all tested doses and shows favorable safety outcomes in a phase 2 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results